产品名称 |
TT人甲状腺髓样癌细胞 |
货号 |
ZQ0232 |
产品介绍 |
TT细胞系是由梁少光等人从77岁甲状腺髓样癌女性患者的针吸活检标本中建立的。TT细胞持续产生高水平的降血钙素和CEA。在更换培养基后24小时和72小时在培养基中检测到的免疫活性的降血钙素浓度分别为3900 pg/百万细胞和7700 pg/百万细胞。72小时后CEA积累浓度超过27 ng/百万细胞。 对裸鼠中诱发的细胞系和肿瘤的染色体分析表明,该细胞为具有多条标记染色体的非整倍体人类核型。
注意事项: |
种属 |
人 |
性别/年龄 |
女/77岁 |
组织 |
甲状腺/髓质 |
疾病 |
遗传性甲状腺髓样癌(NCIt:C46099) |
细胞类型 |
肿瘤细胞 |
形态学 |
上皮细胞 |
生长方式 |
贴壁 |
倍增时间 |
大约83小时 |
培养基和添加剂 |
F12K基础培养基(中乔新舟 货号:ZQ-599 )+10%胎牛血清(中乔新舟 货号:ZQ500-A)+1%双抗(中乔新舟 货号:CSP006) |
推荐完全培养基货号 |
|
生物安全等级 |
BSL-1 |
STR位点信息 |
Amelogenin: X
CSF1PO: 10,13D3S1358: 15
|
培养条件 |
95%空气,5%二氧化碳;37℃ |
抗原表达/受体表达 |
*** |
基因表达 |
*** |
保藏机构 |
ATCC; CRL-1803 ECACC; 92050721 |
供应限制 |
仅供科研使用 |
货号 |
ZM0232 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
CLPUB00116
Leong S.S., Horoszewicz J.S., Shimaoka K., Friedmann M., Kawinski E., Song M.J., Zeigel R.F., Chu T.M., Baylin S.B., Mirand E.A.
A new cell line for study of human medullary thyroid carcinoma.
(In) Advances in thyroid neoplasia; Andreoli M., Monaco H., Robbins J. (eds.); pp.95-108; Field Educational Italia; Roma (1981)
PubMed=3467830; DOI=10.1016/0165-4608(87)90156-7
Tanaka K., Baylin S.B., Nelkin B.D., Testa J.R.
Cytogenetic studies of a human medullary thyroid carcinoma cell line.
Cancer Genet. Cytogenet. 25:27-35(1987)
PubMed=2519210
Kameya T., Kadoya K., Iguchi H.
Characterization and calcitonin secretion of a human well differentiated C-cell tumor cell line.
Hum. Cell 2:231-237(1989)
PubMed=1516062
Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.
Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.
Cancer Res. 52:5061-5064(1992)
DOI=10.1016/B978-0-12-333530-2.50007-1
Carey T.E.
Head and neck tumor cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994)
PubMed=7736432; DOI=10.1016/0165-4608(94)00185-E
Cooley L.D., Elder F.F.B., Knuth A., Gagel R.F.
Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines.
Cancer Genet. Cytogenet. 80:138-149(1995)
PubMed=7864888; DOI=10.1006/bbrc.1995.1287
Carlomagno F., Salvatore D., Santoro M., de Franciscis V., Quadro L., Panariello L., Colantuoni V., Fusco A.
Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line.
Biochem. Biophys. Res. Commun. 207:1022-1028(1995)
PubMed=9046062; DOI=10.14670/HH-12.283
Zabel M., Grzeszkowiak J.
Characterisation of thyroid medullary carcinoma TT cell line.
Histol. Histopathol. 12:283-289(1997)
PubMed=11751535; DOI=10.1093/clinchem/48.1.25
Zammatteo N., Lockman L., Brasseur F., De Plaen E., Lurquin C., Lobert P.-E., Hamels S., Boon T., Remacle J.
DNA microarray to monitor the expression of MAGE-A genes.
Clin. Chem. 48:25-34(2002)
PubMed=19897677; DOI=10.1210/jc.2009-1485
Zhu W., Hai T., Ye L., Cote G.J.
Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on Ret proto-oncogene activity.
J. Clin. Endocrinol. Metab. 95:439-444(2010)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=22538498; DOI=10.1159/000338793
Grozinsky-Glasberg S., Shimon I., Rubinfeld H.
The role of cell lines in the study of neuroendocrine tumors.
Neuroendocrinology 96:173-187(2012)
PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)
PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)
产品名称 | 价格 | 指令 |
TTA1人甲状腺癌细胞(STR鉴定) | ¥1500.00 | 购物车 》 |
B-CPAP人甲状腺癌细胞(STR鉴定) | ¥1800.00 | 购物车 》 |
ACT-1人甲状腺癌细胞(STR鉴定) | ¥1500.00 | 购物车 》 |
CAL-62人甲状腺癌细胞(STR鉴定) | ¥1350.00 | 购物车 》 |
BHT101人甲状腺癌细胞(STR鉴定) | ¥1800.00 | 购物车 》 |
HTh-7人甲状腺癌细胞(STR鉴定)[套餐促销] | ¥1200.00 | 购物车 》 |
Hth83人甲状腺癌细胞(STR鉴定) | ¥1600.00 | 购物车 》 |
KHM-5M人甲状腺癌细胞(STR鉴定) | ¥1350.00 | 购物车 》 |
KMH-2人甲状腺癌细胞(STR鉴定) | ¥1500.00 | 购物车 》 |
KTC-1人甲状腺癌细胞(STR鉴定) | ¥1350.00 | 购物车 》 |
Ocut-2C人甲状腺癌细胞(STR鉴定) | ¥1600.00 | 购物车 》 |
C643人甲状腺癌细胞(STR鉴定)[套餐促销] | ¥1350.00 | 购物车 》 |
支原体检测试剂盒 | ¥800.00 | 购物车 》 |
支原体清除试剂盒 | ¥600.00 | 购物车 》 |
国产转染试剂 | ¥800.00 | 购物车 》 |
慢病毒介导基因沉默或过表达 | ¥询价 | 购物车 》 |
绿/红色荧光蛋白标记 | ¥询价 | 购物车 》 |
优级胎牛血清 | ¥2580(开学促销) | 购物车 》 |
F-12基础培养基 | ¥96.00 | 购物车 》 |
F-12完全培养基 | ¥350.00 | 购物车 》 |